- RSV, a member of the Pneumoviridae virus family, is transmitted through direct contact with infected respiratory secretions and is a significant pathogen of the very young, the immunocompromised, and the elderly
- In new born infants:
- RSV infection causes 1–2 weeks of respiratory tract disease. Only partial protection is achieved following the first infection and subsequent re-infection can occur during the same winter season.
- In the United States, between 100,000 and 126,000 infants under 1 year of age have been hospitalised in each of the previous 5 years. Approximately 2.1 million outpatient consultations for the under-5s occur each year due to RSV.
- The mortality rate in very young at risk infants is between 2% and 3% in most developed countries, including the United States.
- In the immunocompromised or other medically compromised patients:
- Patients who are immunocompromised (e.g due to chemotherapy, or transplantation procedures) are at considerable risk of RSV infection.
- Although numerically less significant, the considerable investment in such patients mandates their treatment.
- In the elderly:
- There is increasing awareness of the burden caused by RSV in the elderly. During years without a major influenza epidemic, RSV is the most significant cause of morbidity and mortality in the over 60s.
- There are more than 2 million consultations with physicians in the United States each year due to RSV infection.
- The virus is also a significant problem in adults with COPD, where it is a major cause of exacerbations.
ReViral has identified a novel, safe and effective molecule: RV521.
- RV521 has been shown in Phase 1 clinical studies to give exposure that exceeds levels predicted for antiviral activity
- RV521 has been shown to be safe in Phase 1 clinical studies no significant adverse events were seen
- RV521 is now in Phase 2a clinical studies in normal healthy volunteers inoculated with RSV
ReViral is focused on the discovery and development of the next generation of antivirals to treat RSV infection. The Company has a Phase 2 clinical stage compound: RV521, an RSV fusion (F) protein inhibitor. The Company also has programmes that inhibit RSV replication by mechanisms other than fusion which are in lead optimisation.
Below is a select list of recent significant publications on antiviral agents and novel approaches from the ReViral team.
Antiviral drugs for acute infections. Comprehensive Medicinal Chemistry III. (2017), Vol 5, Pages 665-681, Powell, KL., Thomas, E., and Cockerill, GS.
The prophylaxis and treatment with antiviral agents of respiratory syncytial virus infections. Antivir Chem Chemother. (2012) 17;22(4):139-50. Najarro, P., Angell, R., and Powell KL.
NS5a Targeting Inhibitors. Hepatitis C: Antiviral Drug Discovery and Development. (2011), Najarro, P., Mathews, N., and Cockerill, GS.
Inhibitors of Respiratory Syncytial Virus. Annual Reports in Medicinal Chemistry. (2008), Vol. 43, Chapter 14. Pages. 229-245. Carter, M. and Cockerill, GS.
RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrobial Agents and Chemotherapy. (2007), 51(9), 3346-3353. Chapman, Joanna; Abbott, Elizabeth; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.; Henderson, Elisa A.; Carter, Malcolm C.; Chambers, Phil; Chubb, Ann; Cockerill, G. Stuart; Collins, Peter L.; Dowdell, Verity C. L.; Keegan, Sally J.; Kelsey, Richard D.; Lockyer, Michael J.; Luongo, Cindy; Najarro, Pilar; Pickles, Raymond J.; Simmonds, Mark; Taylor, Debbie; Tyms, Stan; Wilson, Lara J.; Powell, Kenneth L
1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. Journal of Medicinal Chemistry. (2006), Vol 49, Pages 2311 – 2319. Malcolm C. Carter, Dagmar G. Alber, Robert C. Baxter, Sian K. Bithell, Jo Budworth, Ann Chubb, G. Stuart Cockerill, Verity C. L. Dowdell, Elisa A. Henderson, Sally J. Keegan, Richard D. Kelsey, Michael J. Lockyer, Jeremy N. Stables, Lara J. Wilson, and Kenneth L. Powell.